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Abstract 
Tamoxifen decreased the efflux of the fluorescent marker drug, chloroquine, from phosphatidylcholine liposomes. Tamoxifen is a known 
structural-mimic of cholesterol, which were both found to be similarly effective in preventing drug release from liposomes. This ability of tamoxifen 
and cholesterol to decrease drug efflux in a concentration-dependent ma ner is likely to arise from their known ability to decrease membrane fluidity 
both in liposomes and also in cancer cells. The possible importance of the ability of tamoxifen to inhibit drug efflux from liposomes in relation to 
its ability to reverse multidrug resistance in cancer patients caused by the effiux of cytotoxic therapeutic agents, is discussed. 
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1. Introduction 
Tamoxifen is successfully used in the treatment of 
breast cancer [1-4] and is now being investigated as a 
prophylactic agent for this disease [5-9]. In addition, 
tamoxifen may be of use clinically in the treatment of 
other cancers, including cancer of the liver [10], pancreas 
[11] and brain [12,13]. The ability of tamoxifen to cause 
the production of transforming growth factor fl in nor- 
mal cells, which inhibits the growth of adjacent cancer 
cells [14], suggests that tamoxifen might find general ap- 
plication in the prevention and treatment of cancer. 
Currently there is also considerable interest in the 
potential clinical use of tamoxifen to reverse multidrug 
resistance (MDR) [15], which is an important clinical 
problem. An MDR phenotype can result from the over- 
production in resistant cells of a transmembrane P-170 
glycoprotein (encoded by the mdr-1 gene), which appears 
to act through an ATP-dependent drug-efflux mecha- 
nism to pump the cytotoxic drugs used in cancer chemo- 
therapy (e.g. adriamycin) out of the cell, thus preventing 
the accumulation of drugs to an effective cytotoxic on- 
centration. Tamoxifen has been shown to reverse P-170 
glycoprotein-induced MDR in human and murine leuka- 
emic cells [16] and in P-170 glycoprotein-expressing cell 
lines [17], and also vinblastine resistance in multidrug- 
resistant cell lines [18]. In addition, tamoxifen can in- 
crease the cytotoxic effects of adriamycin and vinblastine 
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[19]. Furthermore, tamoxifen has been used in combina- 
tion with vinblastine as a MDR reversal agent in Phase-I 
clinical trials [20], and high-dose tamoxifen with eto- 
poside is also being studied [21]. 
The recognized ability of tamoxifen to decrease mem- 
brane fluidity [22,23] could directly inhibit the action of 
the P-170 glycoprotein pump, possibly by altering its 
conformation [24,25]. However, an underlying basal 
mechanism for the ability of tamoxifen to prevent drug 
efflux across the lipid bilayer component of membranes 
is also possible. Tamoxifen and related compounds de- 
crease membrane fluidity in phospholipid liposomes [23], 
which are a useful model membrane (lipid bilayer) sys- 
tem [26] for studying possible protein pump-independent 
mechanisms of the anti-MDR action of tamoxifen. We 
investigated, therefore, the ability of tamoxifen and the 
membrane fluidity modulator, cholesterol (structures 
shown in Fig. 1), to modulate drug efflux from li- 
posomes. This was measured by the ettlux of the fluores- 
cent marker drug, chloroquine, from phosphati- 
dylcholine liposomes, which can be readily assayed as a 
model for the cytotoxic drugs administered during can- 
cer chemotherapy treatments that are effluxed by the 
cancer cell. 
2. Materials and methods 
2.1. Chemicals 
Tamoxifen, chloroquine disulphate salt and Sephadex G-50 were 
obtained from Sigma Chemical Co. (Poole, UK); cholesterol was ob- 
tained from Judex Laboratory Reagent (Sudbury, UK); and soya bean 
phosphatidylcholine was obtained from BDH Laboratory Suppliers 
(Poole, UK). 
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2.2. Preparation and purification of liposomes 
Liposomes were prepared with and without he introduction of the 
compounds shown in Fig. 1. Soya bean phosphatidylcholine was dis- 
solved in chloroform to give a final concentration f l0 mg/ml. When 
included, tamoxifen or cholesterol were added to the chloroform to give 
the final concentrations stated. The chloroform was evaporated in a 
rotary evaporator and the residue was sonicated for 40 min with 50 ml 
of chloroquine in aqueous olution (1 mg/ml) to produce liposomes 
(small unilamellar vesicles, SUVs, were formed). The liposomes with 
entrapped chloroquine were separated from the unentrapped chloro- 
quine by gel-filtration with Sephadex G-50. 
2.3. Chloroquine fflux studies 
The efflux of chloroquine, in the absence and presence of a range of 
concentrations of tamoxifen and cholesterol, was determined by meas- 
uring the release of chloroquine from liposomes. Thus 3 ml of the 
purified liposomes in a sealed dialysis bag was placed in 25 rnl glycine 
buffer (pH 9.2) at 25°C and at the times tated 3 ml was removed from 
the buffer and the released chloroquine was determined by fluores- 
cence. The sample was then returned to the buffer to keep the volume 
constant. The fluorescence values were measured using a Perkin-Elmer 
spectrofluorimeter: chloroquine xhibits a fluorescence emission maxi- 
mum at 383 nm (excitation maximum at 330 nm). The amount of 
chloroquine ntrapped was measured by mixing and centrifuging a
2 ml sample of the purified liposome suspension with an equal volume 
of chloroform at 3,000 rpm for 10 min in a bench centrifuge. The 
chloroquine present in 1 ml of the aqueous chloroquine-containing 
layer was determined by the fluorescence technique described above• 
3. Results 
Fig. 2 shows that tamoxi fen,  over  the concentrat ion  
range used o f  0 -50 ¢tM, decreased the efflux o f  ch loro-  
qu ine f rom the l iposomes (amount  released was ex- 
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Fig. 2. Time-course of the effect of (B) 0 ¢tM tamoxifen (control), 
(G) 5/tM tamoxifen, (0) 10 ~M tamoxifen, (&) 25/IM tamoxifen and 
(II,) 50 ktM tamoxifen on the mean amount of chloroquine r lease from 
liposomes as a % of the mean amount of chloroquine ntrapped. Re- 
suits are quoted as the mean of the measurements from two separate 
experiments. 
pressed as a % of  the amount  entrapped) ,  which was 
measured  over  a t ime-course  o f  6 h: similar results were 
obta ined for cholesterol  over  the same concent ra t ion  
range and t ime-course  (Fig. 3). The  effect o f  both  tamox-  
ifen and cholesterol  on ch lo roqu ine  efflux (see Fig. 4) 
was clearly concent ra t ion  dependent ,  and tamoxi fen  and 
cholesterol  appear  to have a similar effect in decreas ing 
the efflux of  ch loroquine.  These results also show (see 
Figs. 2-4)  that for both  tamoxi fen and cholesterol ,  10 
/.tM of  each compound is cons iderably  more  effective 
than 5 HM at decreasing ch loroqu ine  efflux, and, in the 
case o f  cholesterol ,  very little further effect is observed 
at higher concentrat ions:  tamoxi fen concentrat ions  
of  >10 ~M did produce some further increases in effect 
(see Fig. 2) but  at a concent ra t ion  of  approx imate ly  25 
¢tM both  compounds  had reached the same max imum 
level o f  reduct ion in ch lo roqu ine  efflux (see Fig. 4). 
4. Discussion 
CHOLESTEROL R 1 =O11, Rz=CH ( CH 3 ) ( CH 2 ) 3CH (CH 3 ) 2 
Fig. 1. Structures of the triphenylethylene anticancer drug, tamoxifen, 
and the membrane sterol, cholesterol. 
Tamoxi fen  and cholesterol  were both found to de- 
crease the efftux o f  ch loroqu ine  f rom phosphat i -  
dylchol ine l iposomes. Fur thermore ,  over  the concentra-  
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Fig. 3. Time-course of the effect of (B) 0 / IM  cholesterol (control), 
(::) 5/ IM cholesterol, (O) 10 aM cholesterol, (&) 25 ,uM cholesterol and 
(~) 50 tiM cholesterol on the mean amount of chloroquine release from 
liposomes as a % of the mean amount of chloroquine ntrapped. Re- 
sults quoted are the mean of measurements from two separate xperi- 
ments. 
tion range tested, both compounds were similarly effec- 
tive at preventing chloroquine release. This suggests that 
tamoxifen and cholesterol (see Fig. 1) are acting in a 
similar manner to decrease drug efflux, probably 
through a mechanism involving decreased membranes 
fluidity. Tamoxifen has been shown to decrease mem- 
brane fluidity in phospholipid liposomes [23] and in 
human cancer cells [22], and it has been suggested that 
tamoxifen decreases membrane fluidity through a similar 
mechanism to that of cholesterol, which it structurally 
mimics [23,27]. The well-documented ability of cholest- 
erol to stabilize membranes through decreased mem- 
brane fluidity is thought to involve an interaction be- 
tween the rigid hydrophobic ring structure of cholesterol 
and the saturated, mono-unsaturated, and to a much 
lesser extent he poly-unsaturated, fatty acid side chains 
of phospholipids [28,29]. 
This study indicates that the ability of tamoxifen to 
decrease drug efflux from liposomes, probably as a result 
of decreased membrane fluidity, is likely to contribute to 
the ability of tamoxifen to reverse MDR in cancer cells 
[16-21,24,25] through a similar basal mechanism for the 
decreased removal of cytotoxic drugs from the cancer 
cell. This is in addition to the ability of tamoxifen to 
inactivate the P-170 glycoprotein efflux pump that has 
evolved in cancer cells as a particular cause of MDR. 
Inactivation of this superimposed efflux pump-depend- 
ent mechanism as for the basal mechanism reported here 
is proposed to be through decreased membrane fluidity 
[19,22,24,25]. The ability of cholesterol to decrease drug 
efflux to a similar extent o tamoxifen suggests that in- 
creased cholesterol content in the plasma membrane of 
cancer cells and the associated ecrease in membrane 
fluidity could also be beneficial in preventing the cancer 
cell from developing MDR. Cholesterol is likely, there- 
fore, to decrease the basal rate of efflux of an adminis- 
tered cytotoxic drug through the lipid bilayer and to 
contribute to the inactivation of the superimposed P-170 
glycoprotein-dependent mechanism, both as a result of 
the decreased membrane fluidity. The administration of 
other drugs and compounds (in addition to tamoxifen) 
that are known fluidity modulators, e.g. synthetic oestro- 
gens [30], is thus likely to prove a useful approach in 
overcoming the serious clinical problem of MDR. 
This approach could, therefore, be readily extended to 
investigate other drugs of interest. The liposome system 
thus provides a rapid and convenient test for identifying 
the ability of a range of compounds to decrease the un- 
derlying basal rate of drug efflux through a phospholipid 
membrane system in the absence, in the first instance, of 
the protein efflux pump component of cancer cells dis- 
playing this form of MDR. Liposomal systems may, 
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Fig. 4. Concentration-dependent ffect of (A) tamoxifen and (O) 
cholesterol on the mean amount of chloroquine release from liposomes 
as a % of the mean amount of chloroquine ntrapped. Results quoted 
are the mean of measurements from two separate xperiments. 
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therefore, facil itate the development  of  improved agents 
for MDR reversal in cancer cells by prov id ing an aid to 
the identi f icat ion of  appropr iate ly  modif ied versions of  
tamoxi fen and related fluidity modu lators  that have un-  
dergone re-design by computer-predicted molecular  
model l ing for improved efficacy. 
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